3 Wires and Cables Maker, Finished Dosage Generics Maker and Branded Denim Apparel Company Stocks With a Strong Future Roadmap: Polycab India, Strides Pharma Science and Kewal Kiran Clothing
- November 5, 2026
- Posted by: Ankit Jaiswal
- Category: Best Stocks
Polycab India, Strides Pharma Science and Kewal Kiran Clothing: ROE of 15.4% to 24.1% and FY22 to FY26 revenue CAGR of 11.8% to 24.1%. Prices as of 4 Nov 2026.
Quick Answer
The three cable maker, generic drug and denim brand stocks to watch are Polycab India, Strides Pharma Science and Kewal Kiran Clothing. Their return on equity ranges from 15.4% to 24.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 11.8% to 24.1%. Polycab India leads on both return on equity at 24.1% and revenue growth at 24.1% a year. Prices are based on the 4 November 2026 close, and this article is educational, not investment advice.
Cable maker, generic drug and denim brand stocks offer a focused view of a sector where demand keeps widening. Polycab India, Strides Pharma Science and Kewal Kiran Clothing cover a wires and cables maker, a finished dosage generics maker and a branded denim apparel company.
This list covers three cable maker, generic drug and denim brand stocks with complete current figures: Polycab India, Strides Pharma Science and Kewal Kiran Clothing. Every figure comes from the latest reported financials and the 4 November 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Cable Maker, Generic Drug and Denim Brand Stocks?
Cable maker, generic drug and denim brand stocks are listed companies that make wires, cables and consumer electricals, sell finished dosage generics to the United States and other markets, and own denim and casual wear brands sold through stores and online. Their earnings depend on housing and grid spend, drug approvals and apparel demand.
Cable Maker, Generic Drug and Denim Brand Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Polycab India | 7,930 | 115,291 | 36.0 | 42.9 | 24.1 | 0.02 |
| Strides Pharma Science | 1,014.2 | 9,491 | 15.0 | 36.0 | 17.9 | 0.57 |
| Kewal Kiran Clothing | 434.05 | 2,588 | 16.1 | 33.8 | 15.4 | 0.11 |
On valuation, all three trade at a P/E below their industry P/E, which means the market is pricing them at a lower multiple than their peer group. Readers comparing cable maker, generic drug and denim brand stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in cable maker, generic drug and denim brand stocks can use the coming numbers to test whether growth is holding.
Why Do Cable Maker, Generic Drug and Denim Brand Stocks Have a Strong Roadmap in India?
Cable maker, generic drug and denim brand stocks have a strong roadmap in India because strong housing and grid work, wider generic drug demand and rising branded apparel buying keep widening the market for these companies.
- Cables. New buildings and grids need wiring.
- Generic drugs. Regulated markets buy dependable supply.
- Denim apparel. Brand-conscious youth buy more.
Why Polycab India Features Among These Cable Maker, Generic Drug and Denim Brand Stocks
Among the cable maker, generic drug and denim brand stocks on this list, Polycab India is a leading maker of wires and cables, with a growing range of fast moving electrical goods that includes fans, lighting, switches and switchgear, and a project business in engineering and procurement.
Revenue rose from Rs 12,294 crore in FY22 to Rs 29,120 crore in FY26, a compound annual growth rate of 24.1%. Net profit grew from Rs 845 crore in FY22 to Rs 2,708 crore in FY26, which works out to a compound annual growth rate of 33.8%.
The company has a return on equity of 24.1%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 115,291 crore. The stock trades at a P/E of 36.0, below the industry P/E of 42.9.
Roadmap: Spending on housing, power networks and industry is lifting demand for cables, while the company is deepening its presence in consumer electricals through its dealer network. Capacity additions help it serve both retail and project customers.
What to watch: Monitor cable volumes and the growth of its consumer electricals range.
Why Strides Pharma Science Features Among These Cable Maker, Generic Drug and Denim Brand Stocks
Among the electrical, pharma and apparel shares on this list, Strides Pharma Science, based in Bengaluru, makes finished dosage generics for the United States and other regulated markets, with oral solids and soft gel capsules as important product groups.
The company has a return on equity of 17.9%, a debt to equity ratio of 0.57 and a market capitalisation of Rs 9,491 crore. The stock trades at a P/E of 15.0, below the industry P/E of 36.0.
Revenue rose from Rs 3,202 crore in FY22 to Rs 5,009 crore in FY26, a compound annual growth rate of 11.8%. Net profit grew from Rs 409 crore in FY25 to Rs 575 crore in FY26, a rise of 40.3%. In the June 2026 quarter, revenue grew 12.6% year on year to Rs 1,270 crore, while net profit rose 56.7% to Rs 165 crore.
Roadmap: The company is leaning on new product launches in its regulated-market pipeline and improving utilisation of its plants. Profit can rise faster than revenue as volumes build on an existing cost base.
What to watch: Track new US launches and the pace of price erosion in generic categories.
Why Kewal Kiran Clothing Features Among These Cable Maker, Generic Drug and Denim Brand Stocks
Among the three companies on this list, Kewal Kiran Clothing, based in Mumbai, owns the Killer, Easies, Integriti and Lawman Pg3 brands and sells jeanswear and casual apparel through exclusive stores, multi-brand outlets and online channels.
Revenue rose from Rs 625 crore in FY22 to Rs 1,237 crore in FY26, a compound annual growth rate of 18.6%. Net profit grew from Rs 81.6 crore in FY22 to Rs 152 crore in FY26, which works out to a compound annual growth rate of 16.9%.
In the June 2026 quarter, revenue grew 17.9% year on year to Rs 292 crore, while net profit rose 28.2% to Rs 41.0 crore. The company has a return on equity of 15.4%, a debt to equity ratio of 0.11 and a market capitalisation of Rs 2,588 crore. The stock trades at a P/E of 16.1, below the industry P/E of 33.8.
Roadmap: The company is widening its exclusive store network, building its newer brands and adding product categories beyond denim. Control over its own manufacturing helps it respond quickly to fashion trends, and a debt-light balance sheet supports store expansion.
What to watch: Follow same-store sales and the pace at which newer brands scale.
Polycab India vs Strides Pharma Science vs Kewal Kiran Clothing on Key Financials
The table below sets the three cable maker, generic drug and denim brand stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Polycab India | 12,294 | 29,120 | 24.1% | 2,708 | 9.3% |
| Strides Pharma Science | 3,202 | 5,009 | 11.8% | 575 | 11.5% |
| Kewal Kiran Clothing | 625 | 1,237 | 18.6% | 152 | 12.3% |
Polycab India posts the highest return on equity in this group at 24.1%. Polycab India combines the largest FY26 revenue at Rs 29,120 crore with the fastest revenue growth, a 24.1% compound annual rate. A useful habit with cable maker, generic drug and denim brand stocks is to check each new quarterly result against the capacity plans the company described earlier. Many investors spread money across several wires and fans, finished dosage and jeans stocks instead of one name, which keeps a single result from deciding the outcome.
Key Risks to Check Before Investing in Cable Maker, Generic Drug and Denim Brand Stocks
Every theme carries risks that deserve a check before any decision. For these cable maker, generic drug and denim brand stocks, the main points are: Long-term electrical, pharma and apparel shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Input costs. Metal and material prices can move margins.
- Consumer spending. Sales follow festivals, incomes and consumer mood.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter cable maker, generic drug and denim brand stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Cable Maker, Generic Drug and Denim Brand Stocks
Cable maker, generic drug and denim brand stocks reward patient research into demand, execution and financial strength. Polycab India, Strides Pharma Science and Kewal Kiran Clothing each have a clear plan to grow. Based on the 4 November 2026 close, Polycab India trades at Rs 7,930, Strides Pharma Science at Rs 1,014.2 and Kewal Kiran Clothing at Rs 434.05. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these cable maker, generic drug and denim brand stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track cable maker, generic drug and denim brand stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are cable maker, generic drug and denim brand stocks?
Ans. Cable maker, generic drug and denim brand stocks are listed companies that make wires, cables and consumer electricals, sell finished dosage generics to the United States and other markets, and own denim and casual wear brands sold through stores and online. Their earnings depend on housing and grid spend, drug approvals and apparel demand. This list looks at three of them, Polycab India, Strides Pharma Science and Kewal Kiran Clothing, using reported FY22 to FY26 financials and the 4 November 2026 closing prices.
Which cable maker, generic drug and denim brand stocks are covered in this list?
Ans. This list covers Polycab India, Strides Pharma Science and Kewal Kiran Clothing. Based on the 4 November 2026 close, Polycab India traded at Rs 7,930, Strides Pharma Science at Rs 1,014.2 and Kewal Kiran Clothing at Rs 434.05. Their return on equity ranges from 15.4% to 24.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 11.8% to 24.1%.
Why do cable maker, generic drug and denim brand stocks have a strong future roadmap in India?
Ans. Cable maker, generic drug and denim brand stocks have a strong roadmap in India because strong housing and grid work, wider generic drug demand and rising branded apparel buying keep widening the market for these companies. The main drivers are as follows. Cables. New buildings and grids need wiring. Generic drugs. Regulated markets buy dependable supply. Denim apparel. Brand-conscious youth buy more. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Polycab India performed financially?
Ans. Revenue rose from Rs 12,294 crore in FY22 to Rs 29,120 crore in FY26, a compound annual growth rate of 24.1%. Net profit grew from Rs 845 crore in FY22 to Rs 2,708 crore in FY26, which works out to a compound annual growth rate of 33.8%. The company has a return on equity of 24.1%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 115,291 crore. The stock trades at a P/E of 36.0, below the industry P/E of 42.9. Looking ahead, spending on housing, power networks and industry is lifting demand for cables, while the company is deepening its presence in consumer electricals through its dealer network. Capacity additions help it serve both retail and project customers.
How has Strides Pharma Science performed financially?
Ans. Revenue rose from Rs 3,202 crore in FY22 to Rs 5,009 crore in FY26, a compound annual growth rate of 11.8%. Net profit grew from Rs 409 crore in FY25 to Rs 575 crore in FY26, a rise of 40.3%. In the June 2026 quarter, revenue grew 12.6% year on year to Rs 1,270 crore, while net profit rose 56.7% to Rs 165 crore. The company has a return on equity of 17.9%, a debt to equity ratio of 0.57 and a market capitalisation of Rs 9,491 crore. The stock trades at a P/E of 15.0, below the industry P/E of 36.0. Looking ahead, the company is leaning on new product launches in its regulated-market pipeline and improving utilisation of its plants. Profit can rise faster than revenue as volumes build on an existing cost base.
How has Kewal Kiran Clothing performed financially?
Ans. Revenue rose from Rs 625 crore in FY22 to Rs 1,237 crore in FY26, a compound annual growth rate of 18.6%. Net profit grew from Rs 81.6 crore in FY22 to Rs 152 crore in FY26, which works out to a compound annual growth rate of 16.9%. In the June 2026 quarter, revenue grew 17.9% year on year to Rs 292 crore, while net profit rose 28.2% to Rs 41.0 crore. The company has a return on equity of 15.4%, a debt to equity ratio of 0.11 and a market capitalisation of Rs 2,588 crore. The stock trades at a P/E of 16.1, below the industry P/E of 33.8. Looking ahead, the company is widening its exclusive store network, building its newer brands and adding product categories beyond denim. Control over its own manufacturing helps it respond quickly to fashion trends, and a debt-light balance sheet supports store expansion.
What risks should investors check before buying cable maker, generic drug and denim brand stocks?
Ans. Investors should check a few risks before buying cable maker, generic drug and denim brand stocks. Input costs. Metal and material prices can move margins. Consumer spending. Sales follow festivals, incomes and consumer mood. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of cable maker, generic drug and denim brand stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 4 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
